MCL Literature Feed

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

The Endothelial Activation and Stress Index (EASIX) is a novel, independent prognostic biomarker in MCL, with high scores at diagnosis correlating with significantly shorter OS and PFS.

The SOX11:SMARCA4 complex is a key oncogenic driver in MCL, and targeting SMARCA4 with a PROTAC degrader shows preclinical activity, offering a novel therapeutic strategy for relapsed patients.

Preclinical data show CBX5 loss drives PI3Kδ inhibitor resistance in MCL, which is reversed by propolis-derived CAPE via induction of CBX5-mediated ferroptosis, a novel therapeutic strategy.

A novel para-phenylenediamine-based ROR1 inhibitor demonstrates potent preclinical activity against an MCL cell line (JeKo-1), establishing a new chemical scaffold for targeting this promising therapeutic pathway.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

M2-polarized macrophages drive ibrutinib resistance via the CXCL5/CXCR2 axis; a CXCR2 inhibitor re-sensitizes MCL cells, suggesting a novel combination therapy to overcome BTKi resistance.

This organic chemistry paper describes a method for synthesizing complex molecules and has no direct relevance to mantle cell lymphoma clinical research, treatment, or biology.

A case of benign BCL-6-positive cutaneous mantle zone hyperplasia mimics cutaneous lymphoma, highlighting that cyclin-D1 staining remains essential to differentiate this benign entity from cutaneous mantle cell lymphoma.

This review of FDA-approved covalent inhibitors highlights the foundational role of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) in MCL, which established this successful drug development strategy.

IGH/IGK gene rearrangement analysis improves diagnostic accuracy for B-cell lymphomas, with co-occurring IGH and IGK rearrangements being a characteristic feature of mantle cell lymphoma.

The m6A writer METTL3 promotes MCL progression by degrading Ambra1 mRNA via the reader YTHDF2, identifying a novel, potentially targetable therapeutic axis for mantle cell lymphoma.

A case report highlights chylothorax as a rare clinical presentation of mantle cell lymphoma, underscoring the need to consider malignancy in the differential diagnosis of this condition.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This case report of a rectal plasmacytoma misdiagnosed as MCL highlights a critical diagnostic pitfall, emphasizing the need for thorough pathological evaluation to prevent incorrect lymphoma-directed therapy.

This case report describes a rare, rapid progression from acute myopericarditis to pericardial calcification after initial CHOP chemotherapy, highlighting a severe, early-onset cardiotoxicity risk with this regimen.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This first reported case of composite MCL and T-cell prolymphocytic leukemia highlights the diagnostic challenge of co-existing lymphoid malignancies, where an indolent T-PLL clone was present for years before diagnosis.

This MZL case identifies BTK C481S and PLCG2 D334H co-mutations driving zanubrutinib resistance, a mechanism highly relevant to BTKi failure and subsequent treatment strategies in relapsed MCL.